Volume 28, Issue 6 pp. 1812-1819
ORIGINAL ARTICLE

Somatic symptoms have negligible impact on Patient Health Questionnaire-9 depression scale scores in neurological patients

Irene L. Katzan

Irene L. Katzan

Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Center for Outcomes Research and Evaluation, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Brittany Lapin

Corresponding Author

Brittany Lapin

Center for Outcomes Research and Evaluation, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Correspondence

Brittany Lapin, Neurological Institute Center for Outcomes Research & Evaluation, Cleveland Clinic, 9500 Euclid Avenue, JJN3, Cleveland, OH 44195, USA.

Email: [email protected]

Search for more papers by this author
Sandra Griffith

Sandra Griffith

Center for Outcomes Research and Evaluation, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Lara Jehi

Lara Jehi

Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Hubert Fernandez

Hubert Fernandez

Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Erik Pioro

Erik Pioro

Neuromuscular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Stewart Tepper

Stewart Tepper

Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for more papers by this author
Paul K. Crane

Paul K. Crane

Division of General Internal Medicine, University of Washington, Seattle, Washington, USA

Search for more papers by this author
First published: 13 March 2021
Citations: 7

Abstract

Background and purpose

There is concern that the Patient Health Questionnaire-9 (PHQ-9) depression scale may be impacted by the presence of somatic symptoms (differential item functioning [DIF]) in patients with neurological conditions. We evaluated the PHQ-9 for the presence and impact of DIF in large clinical samples of neurological patients.

Methods

We conducted a cross-sectional study of patients seen at the Cleveland Clinic Cerebrovascular, Headache, Movement Disorder, and Neuromuscular clinics who completed the PHQ-9 and patient-reported disease severity measures as part of standard care between 29 July 2008 and 21 February 2013. We evaluated PHQ-9 items for DIF with respect to disease-specific severity for each condition. Salient DIF impact was characterized as a difference between DIF-adjusted and unadjusted PHQ-9 scores.

Results

Included in the study were 2112 patients with stroke, 8221 with migraine, 440 with amyotrophic lateral sclerosis (ALS), and 5022 with Parkinson disease (PD). Several PHQ-9 items demonstrated DIF with respect to disease-specific severity, although salient DIF was present in very few patients (stroke, n = 0; migraine, n = 1; ALS, n = 13; PD, n = 1).

Conclusions

PHQ-9 items function consistently across disease severity, with salient levels of DIF impact found only for a very small proportion of people. These results suggest that the PHQ-9 provides a consistent measure of depression severity among people with neurological conditions associated with somatic symptoms that overlap with depression.

CONFLICT OF INTEREST

The authors declare no financial or other conflicts of interest.

DATA AVAILABILITY STATEMENT

Anonymized data relevant to this study will be shared by request with any qualified investigator pending appropriate institutional review board approvals.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.